# A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R

Study · id `cardio:ct-nct06717360` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06717360](<https://clinicaltrials.gov/study/NCT06717360>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06717360

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 158 participants.

## Technical summary

Registry record NCT06717360. Randomized; quadruple masking; primary purpose treatment. Start 2024-09-30 (actual); primary completion 2025-07-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 158 participants (enrolled count; ClinicalTrials.gov record NCT06717360, source copy `cardio:ctgov-nct06717360-2026-06-18`, retrieved 2026-10-31)
- Started: 2024-09-30 (actual) (ClinicalTrials.gov record NCT06717360, source copy `cardio:ctgov-nct06717360-2026-06-18`, retrieved 2026-10-31)
- Primary completion: 2025-07-10 (actual) (ClinicalTrials.gov record NCT06717360, source copy `cardio:ctgov-nct06717360-2026-06-18`, retrieved 2026-10-31)
- Completion: 2026-05-12 (actual) (ClinicalTrials.gov record NCT06717360, source copy `cardio:ctgov-nct06717360-2026-06-18`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT06717360, source copy `cardio:ctgov-nct06717360-2026-06-18`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06717360-2026-06-18`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R
- Condition: Hypercholesterolemia
- Intervention (Drug): AG2304T
- Intervention (Drug): AG2304R
- Lead sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd (`cardio:org-ahn-gook-pharmaceuticals-co-ltd`)

## Provenance

Content hash: 346fcad270a22c9ad928727564935738af6eb71a500e418eb88c0cdcc394d7bc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
